[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t-lymphoblastic-leukemialymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t-lymphoblastic-leukemialymphoma":142},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,77,101,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100570813","phase-2-venetoclax-and-decitabine-in-rr-t-all-100570813",false,"NCT06712121","Venetoclax and Decitabine in R\u002FR T-ALL","A Phase 2 Clinical Trial to Evaluate the Efficacy of VEnetoclax and DEciTabine in Relapsed\u002FRefractory Adult T-acute Lymphoblastic lEukemia\u002FLymphoma","Inclusion Criteria:\n\n* Adults aged 19 years or older but less than 80 years\n* Eastern Cooperative Oncology Group Performance Score (ECOG PS) ≤ 2\n* Confirmed diagnosis of T-cell lymphoblastic leukemia\u002Flymphoma according to the 2016 World Health Organization criteria, with relapse or failure to achieve complete remission despite induction chemotherapy\n* Patients with peripheral blood leukocytes \\<50,000\u002FuL (reducing white blood cell count through hydroxyurea or leukapheresis prior to trial enrollment is allowed)\n* At the time of screening, a calculated glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin according to the Cockcroft-Gault formulas, or creatinine ≤ 1.4, total bilirubin ≤ 3.0 mg\u002FdL, and AST and ALT \\< x5 upper limit of normal (ULN) (however, if bilirubin elevation is due to Gilbert\\'s syndrome or liver enzyme elevation is due to infiltration of leukemia\u002Flymphoma, enrollment may be allowed even if the above conditions are exceeded)\n* Individuals who agree to the following contraceptive measures for a period of 3 months during treatment and for 3 months after completion:\n\nExclusion Criteria:\n\n* Individuals in complete remission with previous treatment, if relapse or resistance is not confirmed by bone marrow examination or imaging\u002Ftissue examination.\n* Individuals who previously received venetoclax + decitabine treatment for T-lymphoblastic leukemia\u002Flymphoma (participants who received venetoclax + decitabine treatment for a different type of cancer \\[e.g., acute myeloid leukemia\\] and have elapsed more than 1 year since the last treatment are allowed).\n* Pregnant or breastfeeding individuals.\n* Individuals who received systemic anticancer chemotherapy or participated in a clinical trial treatment within the past 2 weeks.\n* Individuals with active leukemia involving the central nervous system.\n* Individuals with a cancer type other than T-lymphoblastic leukemia\u002Flymphoma that requires current active treatment (participants with a cancer type that has already been cured or is in a slow-progressing state without treatment, as determined by surgery\u002Fradiation\u002Fchemotherapy, may participate under the consultation of the clinical trial investigator).\n* Individuals with active human immunodeficiency virus (HIV) infection, hepatitis B\u002Fhepatitis C infection (participants without evidence of viral particles through PCR testing may be enrolled with the consent of an infectious disease specialist or hepatologist).\n* Uncontrolled bleeding.\n* Uncontrolled infection (bacterial, fungal, viral).\n* Uncontrolled mental illness.\n* Individuals who do not understand the informed consent or have difficulty in adequate communication, making them inappropriate for participation in the clinical trial.\n* Cases where the investigator judges that patient evaluation may be hindered or participation in the clinical trial is not appropriate.\n* Individuals who have a negative attitude towards participating in the clinical trial or who are unwilling to comply with the treatment and specimen collection schedule specified in the study protocol.","ALL","19 Years","80 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia\u002Flymphoblastic lymphoma.\n\nThis study use a modified regimen of decitabine and venetoclax.",[27],"T Lymphoblastic Leukemia\u002FLymphoma",[29,30,31],"T lymphoblastic leukemia\u002Flymphoma","venetoclax","decitabine","RECRUITING","2026-01-29",{"date":35,"type":36},"2026-02-02","ACTUAL",{"date":38,"type":36},"2025-01-30",{"date":40,"type":21},"2028-08-31",{"name":42,"class":43},"Seoul National University Hospital","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100604711","phase-1-supcd7-cart-for-relapsed-or-refractory-cd7-positive-hematologic-malignancies-100604711","NCT07153068","SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","Super-universal CD7 CART (supCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.","Inclusion Criteria:\n\n* Age ≥18 and \\\u003C70 years, regardless of gender;\n* T-ALL\u002FLBL was diagnosed according to the criteria of NCCN Clinical Practice Guidelines for Acute Lymphocytic Leukemia (2020.v1) and T-cell Lymphoma Clinical Practice Guidelines (2020.v1);\n* Patients diagnosed with AML with reference to the Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2018 Edition) issued by the Health Commission;\n* Cytology confirmed that the tumor cells were CD7 positive.\n* Number of blasts in bone marrow ≥5% at screening (bone marrow morphology);\n* Complies with the diagnosis of relapsed\u002Frefractory AML, including any of the following conditions according to China Guidelines for Diagnosis and Treatment of Relapsed\u002FRefractory Acute Myeloid Leukemia (2021 Edition): a. Primary refractory patients who did not achieve CR after two cycles of standard induction chemotherapy; b. CR after consolidation chemotherapy, relapse within 12 months; c. Relapse 12 months after remission but ineffective after conventional chemotherapy; d. 2 or more relapses; e. Relapse after hematopoietic stem cell transplantation.\n* Meet the diagnosis of relapsed\u002Frefractory T-ALL\u002FLBL, including any of the following: a. Primary refractory patients who have not achieved complete response after two cycles of standard chemotherapy, or patients who have not achieved complete response after multi-line rescue chemotherapy; b. Relapse within \\\u003C12 months after complete remission or ≥12 months after complete remission and fail to achieve complete remission induced by 1 or more cycles of standard treatment; c. Relapse after hematopoietic stem cell transplantation or relapse after CAR-T therapy at the same target;\n* Complies with diagnosis of other relapsed\u002Frefractory CD7 positive hematologic malignancies\n* Creatine clearance \\>60ml\u002Fmin (Cockcroft and Gault formula); serum total bilirubin ≤3 times the upper limit of normal, serum ALT and AST ≤5 times the upper limit of normal range for patients without liver invasion;\n* showing left ventricular ejection fraction (LVEF) ≥50%;\n* Pulse oxygen saturation ≥92%;\n* The estimated survival time is more than 3 months;\n* score 0-2;\n* Subjects or their legal guardians voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\nSubjects who met any of the following criteria were excluded from the study：\n\n* acute promyelocytic leukemia (APL);\n* Presence of a genetic syndrome such as Fanconi's anemia, Kostmann's syndrome, Shwachman syndrome or any other known syndrome of bone marrow failure;\n* Patients with uncontrolled active central nervous system leukemia (CNSL), i.e. cerebrospinal fluid grades CNS 2 and CNS 3;\n* Patients who have received anti-tumor therapy before infusion should be excluded if any of the following conditions are met: a. Systemic chemotherapy (except for pretreatment) within 1 week; b. For those who have received monoclonal antibody therapy, the last time of monoclonal antibody infusion is less than 5 half-lives or 4 weeks (whichever is shorter) at screening; c. Received donor lymphocyte infusion (DLI) within 6 weeks;\n* Presence of uncontrolled, serious, active infection at screening;\n* Patients with a history of serious heart disease, including: severe cardiac insufficiency (subjects with cardiac insufficiency of Class III or IV according to the New York Heart Association (NYHA) cardiac function classification standard), myocardial infarction within 12 months or cardiac angioplasty or stenting, unstable angina pectoris, ECG indicating significant QT interval prolongation (\\>480ms) or serious arrhythmia judged by the investigator;\n* Previous craniocerebral trauma, disturbance of consciousness, epilepsy, cerebral ischemia, cerebral vascular hemorrhagic disease and other medical history, and within six months of the need for drug treatment;\n* Patients with hepatitis B surface antigen (HBsAg) greater than 10E6 IU\u002FmL, hepatitis C virus (HCV) antibody positive, human immunodeficiency virus (HIV) antibody positive, syphilis antibody test positive, EBER positive or EBV copy number greater than the upper limit of normal at screening;\n* Patients who must use steroid hormones during CAR-T infusion (except for local or inhaled steroid hormones); subjects who are receiving systemic steroid therapy before screening and need long-term systemic steroid therapy during treatment according to the investigator's judgment (except for inhaled or local use);\n* Subjects with autoimmune diseases requiring treatment, immunodeficient subjects, or subjects requiring immunosuppressive treatment;\n* Patients with acute graft-versus-host disease (GvHD) or moderate-to-severe chronic GvHD within 4 weeks prior to screening;\n* Patients with a history of allergy to any component of cell products;\n* Pregnant, lactating females, and subjects (male or female) of childbearing potential who are unable to use effective contraception within 1 year after cell infusion; male subjects who plan to become pregnant within 1 year after cell infusion; female subjects or partners who plan to become pregnant within 1 year after cell infusion;\n* Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the trial.","18 Years","70 Years",{"count":55,"type":21},12,[57,24],"PHASE1","The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed\u002Frefractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase Ⅰ+Ⅱ clinical trial, two cohorts were set up: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory T-ALL\u002FLBL cohort. Each cohort was planned to enroll 4-12 patients. SupCD7 CART cells will be administered intravenously to explore the MTD of each cohort using a 3+3 dose escalation and rapid titration design.",[27,60],"Acute Myeloid Leukemia (AML)",[62,63,64,65,66],"Super-universal CD7 CAR-T (supCD7 CAR-T)","Acute myeloid leukemia (AML)","T lymphoblastic leukemia\u002Flymphoma (T-ALL\u002FLBL)","Prospective study","Single-arm Clinical Study","2025-12-11",{"date":69,"type":36},"2025-12-15",{"date":71,"type":36},"2025-06-28",{"date":73,"type":21},"2030-06-28",{"name":75,"class":43},"Institute of Hematology & Blood Diseases Hospital, China",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100611730","phase-2-phase-ii-trial-of-s101-autologous-anti-cd7-car-t-cells-in-patients-with-rr-t-lblall-100611730","NCT07244380","Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R\u002FR T-LBL\u002FALL.","A Phase II Clinical Trial of S101 Autologous CAR-T Cell Injection for the Treatment of CD7-Positive Relapsed or Refractory T-Lymphoblastic Lymphoma\u002FLeukemia (T-LBL\u002FALL).","Inclusion Criteria:\n\n* 1.The subject or guardian must provide voluntary informed consent; 2.Heavily pretreated patients with relapsed or refractory T-LBL\u002FALL who lack effective therapeutic alternatives; 3.At screening, CD7 positivity of tumor cells must be documented by flow cytometry (on bone marrow or peripheral blood samples) and\u002For by immunohistochemistry (IHC) confirming CD7 expression on an extramedullary lesion biopsy; 4.If malignant cells are detected in the peripheral blood at screening, they must demonstrate a CD4-negative and CD8-negative (double-negative) immunophenotype as assessed by flow cytometry; 5.Male or female subjects, aged 18 to 75 years (inclusive); 6.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; 7.Estimated survival time\\>12 weeks.\n\nExclusion Criteria:\n\n* 1.Patients with a history of allogeneic hematopoietic stem cell transplantation within the past 6 months are excluded; 2.Active or uncontrolled infection requiring systemic treatment at screening, excluding mild genitourinary and upper respiratory infections； 3.Participation in another clinical trial within 4 weeks prior to signing the informed consent form (ICF), OR the date of ICF signing occurring within 5 half-lives of the last dose from a previous investigational drug trial (whichever timeframe is longer); 4.Patients with previous treatment involving CAR-T cells or other gene-modified cell therapies are excluded; 5.Patients with acute GVHD (aGVHD) or moderate-to-severe chronic GVHD (cGVHD) within 4 weeks prior to screening, or those who have received systemic pharmacologic therapy for GVHD within 4 weeks prior to infusion; 6.Patients who have received extensive radiotherapy within 4 weeks prior to ICF signing, with the exception of non-target lesion radiotherapy administered for symptomatic palliation that may be permitted during the study period; 7.Women who are pregnant or lactating; 8.Any condition that, in the judgment of the Investigator, could increase the subject's risk or compromise the interpretation of the trial results.","75 Years",{"count":86,"type":21},38,[24],"To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL\u002FALL.",[27],"NOT_YET_RECRUITING","2025-11-17",{"date":93,"type":36},"2025-11-24",{"date":95,"type":21},"2025-11-28",{"date":97,"type":21},"2028-06-30",{"name":99,"class":100},"Hebei Senlang Biotechnology Inc., Ltd.","INDUSTRY",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":119,"locationsCount":76},"100601363","phase-1-ucd7-cart-for-relapsed-or-refractory-cd7-positive-hematologic-malignancies-100601363","NCT07109518","uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","Universal CD7 CART (uCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.","Inclusion Criteria:\n\n1. Age ≥18 and \\\u003C70 years, regardless of gender;\n2. T-ALL\u002FLBL was diagnosed according to the criteria of NCCN Clinical Practice Guidelines for Acute Lymphocytic Leukemia (2020.v1) and T-cell Lymphoma Clinical Practice Guidelines (2020.v1);\n3. Patients diagnosed with AML with reference to the Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2018 Edition) issued by the Health Commission;\n4. Cytology confirmed that the tumor cells were CD7 positive.\n5. Number of blasts in bone marrow ≥5% at screening (bone marrow morphology);\n6. Complies with the diagnosis of relapsed\u002Frefractory AML, including any of the following conditions according to China Guidelines for Diagnosis and Treatment of Relapsed\u002FRefractory Acute Myeloid Leukemia (2021 Edition):\n\n   1. Primary refractory patients who did not achieve CR after two cycles of standard induction chemotherapy;\n   2. CR after consolidation chemotherapy, relapse within 12 months;\n   3. Relapse 12 months after remission but ineffective after conventional chemotherapy;\n   4. 2 or more relapses;\n   5. Relapse after hematopoietic stem cell transplantation.\n7. Meet the diagnosis of relapsed\u002Frefractory T-ALL\u002FLBL, including any of the following:\n\n   1. Primary refractory patients who have not achieved complete response after two cycles of standard chemotherapy, or patients who have not achieved complete response after multi-line rescue chemotherapy;\n   2. Relapse within \\\u003C12 months after complete remission or ≥12 months after complete remission and fail to achieve complete remission induced by 1 or more cycles of standard treatment;\n   3. Relapse after hematopoietic stem cell transplantation or relapse after CAR-T therapy at the same target;\n8. Complies with diagnosis of other relapsed\u002Frefractory CD7 positive hematologic malignancies\n9. Creatine clearance \\>60ml\u002Fmin (Cockcroft and Gault formula); serum total bilirubin ≤3 times the upper limit of normal, serum ALT and AST ≤5 times the upper limit of normal range for patients without liver invasion;\n10. Echocardiography showing left ventricular ejection fraction (LVEF) ≥50%;\n11. Pulse oxygen saturation ≥92%;\n12. The estimated survival time is more than 3 months;\n13. ECOG score 0-2;\n14. Subjects or their legal guardians voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\nSubjects who met any of the following criteria were excluded from the study:\n\n1. acute promyelocytic leukemia (APL);\n2. Presence of a genetic syndrome such as Fanconi's anemia, Kostmann's syndrome, Shwachman syndrome or any other known syndrome of bone marrow failure;\n3. Patients with uncontrolled active central nervous system leukemia (CNSL), i.e. cerebrospinal fluid grades CNS 2 and CNS 3;\n4. Patients who have received anti-tumor therapy before infusion should be excluded if any of the following conditions are met:\n\n   1. Systemic chemotherapy (except for pretreatment) within 1 week;\n   2. For those who have received monoclonal antibody therapy, the last time of monoclonal antibody infusion is less than 5 half-lives or 4 weeks (whichever is shorter) at screening;\n   3. Received donor lymphocyte infusion (DLI) within 6 weeks;\n5. Presence of uncontrolled, serious, active infection at screening;\n6. Patients with a history of serious heart disease, including: severe cardiac insufficiency (subjects with cardiac insufficiency of Class III or IV according to the New York Heart Association (NYHA) cardiac function classification standard), myocardial infarction within 12 months or cardiac angioplasty or stenting, unstable angina pectoris, ECG indicating significant QT interval prolongation (\\>480ms) or serious arrhythmia judged by the investigator;\n7. Previous craniocerebral trauma, disturbance of consciousness, epilepsy, cerebral ischemia, cerebral vascular hemorrhagic disease and other medical history, and within six months of the need for drug treatment;\n8. Patients with hepatitis B surface antigen (HBsAg) greater than 10E6 IU\u002FmL, hepatitis C virus (HCV) antibody positive, human immunodeficiency virus (HIV) antibody positive, syphilis antibody test positive, EBER positive or EBV copy number greater than the upper limit of normal at screening;\n9. Patients who must use steroid hormones during CAR-T infusion (except for local or inhaled steroid hormones); subjects who are receiving systemic steroid therapy before screening and need long-term systemic steroid therapy during treatment according to the investigator's judgment (except for inhaled or local use);\n10. Subjects with autoimmune diseases requiring treatment, immunodeficient subjects, or subjects requiring immunosuppressive treatment;\n11. Patients with acute graft-versus-host disease (GvHD) or moderate-to-severe chronic GvHD within 4 weeks prior to screening;\n12. Patients with a history of allergy to any component of cell products;\n13. Pregnant, lactating females, and subjects (male or female) of childbearing potential who are unable to use effective contraception within 1 year after cell infusion; male subjects who plan to become pregnant within 1 year after cell infusion; female subjects or partners who plan to become pregnant within 1 year after cell infusion;\n14. Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the trial.",{"count":55,"type":21},[57],"The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed\u002Frefractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase 1 clinical trial, two cohorts were set up: (1) relapsed and refractory acute myeloid leukemia (AML) cohort; and (2) relapsed and refractory T lymphoblastic leukemia\u002Flymphoma (T-ALL\u002FLBL) cohort. Each cohort was planned to enroll 4-12 patients. uCD7 CART cells will be administered intravenously to explore the maximum tolerated dose (MTD) of each cohort using a 3+3 dose escalation and rapid titration design.",[60,27],[113,63,64,65,66],"Universal CD7 CAR-T (uCD7 CAR-T)","2025-08-26",{"date":116,"type":36},"2025-09-03",{"date":71,"type":36},{"date":73,"type":21},{"name":75,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":84,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":76},"100486946","cd7-car-t-cells-in-t-cell-lymphomaleukemia-100486946","NCT05620680","CD7 CAR-T Cells in T-cell Lymphoma\u002FLeukemia","Study of CD7 CAR-T Cells in Adult Refractory and Recurrent T-cell Lymphoma\u002FLeukemia","Inclusion Criteria:\n\n1. Age 18-75 (≥ 18 years old, ≤ 75 years old), gender is not limited;\n2. The subject voluntarily participates in the research and signs the \"Informed Consent\" by himself or his legal guardian;\n3. According to the National Comprehensive Cancer Network (NCCN) T lymphocytic lymphoma (2020.V1)\u002Facute lymphoblastic leukemia (2020. V1) practice guidelines, diagnosed with T-cell lymphoma;\n4. Meet the diagnostic criteria for relapsed\u002Frefractory T-cell lymphoma, including any of the following:\n\n1\\) Failure to obtain CR at the end of induction therapy; 2) Patients who have obtained CR have blasts in peripheral blood or bone marrow (proportion \\>5%), or extramedullary diseases; 5. Have not received antibody therapy within 2 weeks before cell therapy; 6. ECOG score of 0-2; 7. The subject has no contraindications to peripheral apheresis; 8. Expected survival time of more than 3 months.\n\nExclusion Criteria:\n\n1. Those who have a history of allergy to any of the ingredients in cell products;\n2. Laboratory tests for the following: including but not limited to, total serum bilirubin≧ 1.5mg\u002Fdl; Serum ALT or AST greater than 2.5 times the upper limit of normal; Blood creatinine≧ 2.0mg\u002Fdl; Platelet count≦ 10×109\u002FL;\n3. Patients with cardiac insufficiency who belong to class III or IV according to the New York Cardiology Association (NYHA) cardiac function grading standards; or echocardiography with left ventricular ejection fraction (LVEF) \\\u003C 50%;\n4. Abnormal lung function, blood oxygen saturation under indoor air \\\u003C 92%;\n5. Myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other serious clinical heart disease within 12 months before enrollment;\n6. Grade 3 hypertension with poor control of blood pressure with medication;\n7. Patients with other advanced tumors (those who are assessed as stable after treatment of other tumors can be enrolled);\n8. Previous head trauma, impaired consciousness, epilepsy, more serious cerebral ischemia or cerebral hemorrhage disease;\n9. Known central nervous system leukemia (CNS2 or CNS3), resistance to intrathecal chemotherapy injections and\u002For ongoing head and\u002For spinal radiation therapy; Previous CNS history but has been effectively controlled to allow enrollment;\n10. Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressant therapy;\n11. presence of uncontrolled, active infection;\n12. Have previously used any CAR-T cell product or other genetically modified T cell therapy;\n13. Live vaccination within 4 weeks prior to enrollment;\n14. HIV, HBV, HCV and TPPA\u002FRPR infections, and HBV carriers;\n15. Subject has a history of alcoholism, drug addiction or mental illness;\n16. The subject has participated in any other clinical research within 3 months before joining this clinical study;\n17. Female subjects have any of the following conditions: a) are pregnant\u002Flactating; or b) have plans to become pregnant during the trial; or c) are of childbearing potential and unable to use effective contraception;\n18. There are other circumstances in which the investigator believes that the subject is not suitable for this study.",{"count":128,"type":21},20,[130],"NA","T-cell lymphoma\u002Fleukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.\n\nIn this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma\u002Fleukemia.",[27],"2022-11-11",{"date":135,"type":36},"2022-11-17",{"date":137,"type":36},"2022-10-01",{"date":139,"type":21},"2028-10-31",{"name":141,"class":43},"Shenzhen University General Hospital","T-Lymphoblastic Leukemia\u002FLymphoma"]